5767-35-1

Basic information

• Product Name: 4-Chloro-6-hydrazinopyrimidine
• Synonyms: 4-CHLORO-6-HYDRAZINOPYRIMIDINE;4(1H)-Pyrimidinone, 6-chloro-, hydrazone (9CI);(6-chloropyrimidin-4-yl)hydrazine;4-chloro-6-hydrazinylpyriMidine;4-Chloro-6-hydrazinopyriMidine, 95+%
• CAS NO: 5767-35-1
• Molecular Formula: C₄H₅ClN₄
• Molecular Weight: 144.56
• Product Categories: PYRIMIDINE;Heterocycle-Pyrimidine series
• Mol File: 5767-35-1.mol
• Article Data: 22

Chemical Properties

• Melting Point: 164-165 °C
• Boiling Point: 328.3 °C at 760 mmHg
• Flash Point: 152.4 °C
• Appearance: White to off-white crystalline powder
• Density: 1.53 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 7.29±0.70(Predicted)
• CAS DataBase Reference: 4-Chloro-6-hydrazinopyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-6-hydrazinopyrimidine(5767-35-1)
• EPA Substance Registry System: 4-Chloro-6-hydrazinopyrimidine(5767-35-1)

Safety Data

• Hazardous Substances Data: 5767-35-1(Hazardous Substances Data)

Usage

General Description

4-Chloro-6-hydrazinopyrimidine is a chemical compound with the molecular formula C5H4ClN5. It is a heterocyclic compound containing a pyrimidine ring with a chlorine atom at the 4th position and a hydrazine group at the 6th position. This chemical is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It is also known for its use in the production of dyes and pigments. 4-Chloro-6-hydrazinopyrimidine is considered to be a potentially hazardous compound due to its reactivity and should be handled with caution in a controlled laboratory environment.

Upstream product

• 1193-21-1 4,6-dichloropyrimidine 

Downstream Products

• 22930-71-8 pyrimidin-4-ylhydrazine 
• 99469-77-9 (6-methylsulfanylpyrimidin-4-yl)hydrazine 
• 1018473-22-7 C₈H₈ClN₅ 
• 1254710-14-9 2-phenylpropionaldehyde (6-chloro-4-pyrimidinyl)hydrazone 
• 1254710-07-0 2-bromo-4,5-dimethoxybenzaldehyde (6-chloro-4-pyrimidinyl)hydrazone 
• 113312-05-3 p-chlorobenzaldehyde (6-chloro-4-pyrimidinyl)hydrazone 
• 1254710-03-6 o-chlorobenzaldehyde (6-chloro-4-pyrimidinyl)hydrazone 
• 68588-40-9 benzaldehyde (6-chloro-4-pyrimidinyl)hydrazone 
• 1254710-08-1 4-methoxybenzaldehyde (6-chloro-4-pyrimidinyl)hydrazone 
• 1254710-04-7 2,4-dichlorobenzaldehyde (6-chloro-4-pyrimidinyl)hydrazone 
• 1254710-06-9 p-bromobenzaldehyde (6-chloro-4-pyrimidinyl)hydrazone 
• 1254710-09-2 o-methylbenzaldehyde (6-chloro-4-pyrimidinyl)hydrazone 
• 1254710-05-8 o-bromobenzaldehyde (6-chloro-4-pyrimidinyl)hydrazone 
• 631914-55-1 Boc-L-Ala-Cl 

Relevant articles and documents

Novel pyrimidine derivatives as potential anticancer agents: Synthesis, biological evaluation and molecular docking study

In the present paper, new pyrimidine derivatives were designed, synthesized and analyzed in terms of their anticancer properties. The tested compounds were evaluated in vitro for their antitu-mor activity. The cytotoxic effect on normal human dermal fibroblasts (NHDF) was also determined. According to the results, all the tested compounds exhibited inhibitory activity on the proliferation of all lines of cancer cells (colon adenocarcinoma (LoVo), resistant colon adenocarcinoma (LoVo/DX), breast cancer (MCF-7), lung cancer (A549), cervical cancer (HeLa), human leukemic lymphoblasts (CCRF-CEM) and human monocytic (THP-1)). In particular, their feature stronger influence on the activity of P-glycoprotein of cell cultures resistant to doxorubicin than doxorubicin. Tested compounds have more lipophilic character than doxorubicin, which determines their affinity for the molecular target and passive transport through biological membranes. Moreover, the inhibitory potential against topoisomerase II and DNA intercalating properties of synthesized compounds were analyzed via molecular docking.

In silico and in vitro Antitubercular Studies for Nitrogen Rich Hybrids of homopiperazine-pyrimidine-Pyrazole Adducts

Novel homopiperazine-pyrimidine-pyrazole hybrids (3a-j) were synthesized using ethyl 2-cyanoacetate and 4,6-dichloropyrimidine as starting materials by a multi-step process to afford ethyl 5-amino-1-(6-chloropyrimidin-4-yl)-1H-pyrazole-4-carboxylate in good yields using polar protic media. The intermediate 1, in two steps, chloroamine condensation followed by acid amine coupling, furnished the title compounds ethyl 5-amino-1-(6-(4-substituted aryl-1,4-diazepan-1-yl)pyrimidin-4-yl)-1H-pyrazole-4-carboxylate (3a-j). The synthesized compounds were docked in the crystal structure of Mycobacterium tuberculosis (PDB ID: 4TRO) to get insights into structural requirements for antitubercular activity. In vitro antitubercular activity against M. tuberculosis H37Rv strains showed that compounds 3a, 3d, 3e and 3g were found to be the most potent (Docking score: > -21; MIC = 1.6 μg/mL) among the synthesized molecules. All the synthesized compounds showed acceptable drug-like properties which make them suitable for further lead modification using in silico design approaches.

GPR52 MODULATOR COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1): (1) and salts thereof, wherein R1, Q, X, Y and Z are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.